SAMSUNG PHARM. Co., LTD. (001360.KS)
- Previous Close
1,609.00 - Open
1,609.00 - Bid 1,617.00 x --
- Ask 1,620.00 x --
- Day's Range
1,580.00 - 1,632.00 - 52 Week Range
1,388.00 - 2,220.00 - Volume
266,009 - Avg. Volume
262,340 - Market Cap (intraday)
152.193B - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, mixed vitamins, antibiotics, and others. The company also provides medicines for digestive system, medicines for liver disorder, medicines for circulation system, cold medicines, nutritional supplements, health tonics, antophlegm agents, and others, as well as quasi-medicines, vitamins and energy drinks, and functional foods. The company was founded in 1929 and is headquartered in Hwaseong-si, South Korea.
www.sspharm.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 001360.KS
View MorePerformance Overview: 001360.KS
Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 001360.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 001360.KS
View MoreValuation Measures
Market Cap
152.19B
Enterprise Value
150.99B
Trailing P/E
5.37
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.50
Price/Book (mrq)
1.06
Enterprise Value/Revenue
3.47
Enterprise Value/EBITDA
4.98
Financial Highlights
Profitability and Income Statement
Profit Margin
28.70%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
44.29B
Net Income Avi to Common (ttm)
12.71B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
11.22B
Total Debt/Equity (mrq)
10.66%
Levered Free Cash Flow (ttm)
--